Immunity to Tumour Antigens

Title: Immunity to Tumour Antigens

Volume: 11 Issue: 27

Author(s): G. Li, S. A. Ali, S. E.B. McArdle, S. Mian, M. Ahmad, A. Miles and R. C. Rees

Affiliation:

Keywords: tumour antigen, immunotherapy, antigen discovery, tolerance

Abstract: During the last decade, a large number of human tumour antigens have been identified. These antigens are classified as tumour-specific shared antigens, tissue-specific differentiation antigens, overexpressed antigens, tumour antigens resulting from mutations, viral antigens and fusion proteins. Antigens recognised by effectors of immune system are potential targets for antigen-specific cancer immunotherapy. However, most tumour antigens are self-proteins and are generally of low immunogenicity and the immune response elicited towards these tumour antigens is not always effective. Strategies to induce and enhance the tumour antigen-specific response are needed. This review will summarise the approaches to discovery of tumour antigens, the current status of tumour antigens, and their potential application to cancer treatment.

Cite this article as:

Li G., Ali A. S., McArdle E.B. S., Mian S., Ahmad M., Miles A. and Rees C. R., Immunity to Tumour Antigens, Current Pharmaceutical Design 2005; 11 (27) . https://dx.doi.org/10.2174/138161205774414583